Chinese Academy of

Iron Isomaltoside injection is a small-molecule intravenous iron supplement under investigation for obesity by Xiyuan Hospital of China Academy of Chinese Medical Sciences (internal code 2024-HX-133). The program combines iron sucrose (VENOFER, approved in the US and Australia) and carisoprodol (an oral muscle relaxant approved across multiple US sponsors) in an injection formulation. The mechanism of action for obesity treatment is not yet disclosed. The program remains active with a latest milestone dated 19 November 2025, though specific milestone details and development phase are not yet disclosed. Clinical trial NCT07236788 is registered. Iron sucrose is an established supplement with multiple approved generic sponsors globally, while carisoprodol is a well-known approved oral agent. The obesity indication represents a novel therapeutic application for this iron-based formulation, positioning it within a competitive landscape that includes GLP-1 receptor agonists and other small-molecule obesity treatments.

Obesity remains a significant unmet medical need with limited pharmacological treatment options beyond lifestyle modification and bariatric surgery. The global obesity market is expanding rapidly, driven by increasing prevalence and growing demand for non-surgical interventions. Current approved therapies include GLP-1 receptor agonists (semaglutide, tirzepatide) and combination agents, but these carry tolerability concerns and high costs. An iron-based injectable formulation targeting obesity would represent a novel mechanism and potentially offer a differentiated safety and efficacy profile if clinical evidence supports efficacy. The patient population for obesity treatment spans millions globally, with significant commercial opportunity in both developed and emerging markets. Xiyuan Hospital's sponsorship suggests integration with traditional Chinese medicine principles, potentially appealing to Asian markets. However, the mechanistic rationale for iron supplementation in obesity treatment is not disclosed, requiring clinical evidence to establish clinical and commercial viability. Competitive positioning depends on efficacy, safety, tolerability, and cost relative to established GLP-1 agonists and emerging alternatives.

Drug Class: Small-molecule iron supplement injection (combination formulation)

Modality: Small molecule

Route of Administration: Intravenous injection

Active Components:

• Iron sucrose (VENOFER brand): intravenous iron supplement with established regulatory approval in the US (NDA021135 and multiple ANDAs) and Australia (PBS codes 10229J, 8807M, first listed 2005 and 2015)
• Carisoprodol: oral muscle relaxant with US approval across 26 sponsors (NDA011792, NDA012155, and 24 ANDAs)

Mechanism of Action: Not yet disclosed for the obesity indication

Target: Not yet disclosed

Related Therapies: Iron sucrose is used clinically for iron deficiency anemia in chronic kidney disease and hemodialysis patients. Carisoprodol is used for musculoskeletal pain. The combination for obesity represents a novel application.

Patent Status: Not yet disclosed

United States: Iron sucrose (VENOFER) is approved via NDA021135 and multiple ANDAs (ANDA208977, ANDA212340, ANDA212559) with sponsors including AM REGENT, International Medication Systems, Mylan Labs Ltd, and Sandoz. Carisoprodol is approved via NDA011792 and NDA012155 with 24 additional ANDA approvals across multiple sponsors. The Iron Isomaltoside injection combination formulation regulatory status in the US is not yet disclosed.

Australia: Iron sucrose (VENOFER) is approved with PBS codes 10229J and 8807M, sponsored by Seqirus (Australia) Pty Ltd, first listed 2005-04-01 and 2015-04-01.

China: Clinical trials are registered (NCT07236788 and multiple other NCT IDs listed: NCT03062774, NCT04493840, NCT05154630, NCT05164458, NCT05171790, NCT05405621, NCT05489276, NCT05584800, NCT05619926, NCT05735496). Regulatory status in China (NMPA) for the obesity indication is not yet disclosed.

EMA/Europe: Regulatory status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

Strategic Implications: Xiyuan Hospital's sponsorship of an iron-based obesity treatment suggests potential integration with traditional Chinese medicine frameworks, targeting Asian markets where such approaches have cultural resonance. The combination of iron sucrose (established supplement) and carisoprodol (approved muscle relaxant) in an injection formulation is unconventional for obesity treatment, indicating either a novel mechanistic hypothesis or repurposing strategy not yet disclosed in public records.

Clinical Development Gaps: The absence of disclosed mechanism of action, target, development phase, and trial design details creates significant uncertainty. The program's active status with a recent milestone (November 2025) suggests ongoing activity, but lack of transparency on trial endpoints, participant numbers, and interim data limits assessment of clinical viability.

Competitive Implications: If efficacy is demonstrated, an intravenous iron-based therapy could differentiate from oral GLP-1 agonists through different mechanism, route, and tolerability profile. However, the competitive landscape is dominated by well-established GLP-1 agonists with robust clinical evidence and market penetration. Differentiation requires clear clinical superiority or safety advantage.

Regulatory Pathway: The program's registration in China (multiple NCT IDs) suggests potential NMPA pathway priority. US and European regulatory pathways are not yet disclosed. The combination of two established components (iron sucrose + carisoprodol) may enable expedited review if safety data are compelling.

Future Catalysts: Publication of NCT07236788 results, disclosure of mechanism of action, phase advancement announcements, and regulatory submissions in China or other major markets.